Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOARER-E: Long-term sirolimus extension in relapsed/refractory acquired chronic pure red cell aplasia
jRCTs031250490Recruiting
- Sponsor
- AMED
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in pure red cell aplasia (PRCA), sponsored by AMED. Primary endpoint: long term safety: frequency of adverse events. Started Nov 2025; status: recruiting.
02
Drugs
sirolimus
03
Conditions
pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on jRCTs031250490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250490.